Immuron (ADR) (IMRN)
Oral bovine-colostrum products for digestive health and travelers’ diarrhea.
Something off on this page? Send us feedback.
Sells Travelan and related hyperimmune bovine-colostrum products through consumer-health channels, while seeking external partners for its clinical assets. Commercial sales are concentrated in Travelan and Australia, with manufacturing and research conducted through outside suppliers and collaborators.
Builds orally delivered hyperimmune bovine-colostrum products whose antibodies are formulated to remain active in the gastrointestinal tract. Travelan, its commercial core, is marketed for travelers’ diarrhea risk reduction and digestive-tract protection; Protectyn and ProIBS extend the Australian consumer portfolio. Sales flow through pharmacies, distributors, travel clinics, Amazon, and Walmart, mainly in Australia with a U.S. and Canadian presence.
Operates with a small workforce and outsourced manufacturing, while academic and U.S. Department of Defense collaborators support research. Its clinical assets are being offered for external development and commercialization partnerships, leaving future program funding and execution dependent on licensees and research partners. Travelan supplies nearly all customer revenue and has different regulatory status across Australia, Canada, and the United States.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $0 · Total assets $9.3M · Shareholders' equity $7.9M
- Revenue
- $2.6M
- Operating income
- −$1.8M
- Net income
- −$1.4M
Reported in AUD, converted at the latest exchange rate
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 1.32% | 84.9K ADS | |
| Insiders5 holders · as of May 14, 2026 | 2.42% | 156.3K ADS | |
| Otherremainder | 96.26% | 6.20M ADS |
6.45M ADS (1 ADS = 40 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Jun 2025 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Steven George LydeamoreInsiderofficer: Chief Executive Officer | 1.22% | 3.16M ordinary | Form 4filed Apr 29, 2026 ↗ |
Morgan StanleyInstitution | 0.47% | 30,574 ADS | 13Fas of Mar 31, 2026 |
Flavio PalumboInsiderofficer: Chief Commercial Officer | 0.44% | 1.14M ordinary | Form 4filed May 14, 2026 ↗ |
Ravi SavarirayanInsiderdirector | 0.34% | 877,840 ordinary | Form 4filed Apr 29, 2026 ↗ |
Daniel Jude PollockInsiderdirector | 0.29% | 743,230 ordinary | Form 4filed May 14, 2026 ↗ |
| See all 14 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Procter & Gamble
Pepto-Bismol is an OTC bismuth alternative for travelers' diarrhea.
- Bausch Health
XIFAXAN is a prescription rifaximin treatment for travelers' diarrhea.
- Kenvue
Imodium provides a global OTC loperamide alternative for diarrhea relief.
- Acurx Pharmaceuticals
Ibezapolstat targets treatment and recurrence prevention in C. difficile.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immuron (ADR) | $1.18 | 0.00% | $7.5M | — | — | 1.2 | +14.9% |
| Procter & Gamble | $147.66 | +0.01% | $350.97B | 22.3 | 21.1 | 4.0 | +1.5% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Kenvue | $19.07 | −0.28% | $36.73B | 22.0 | 16.0 | 2.4 | +3.0% |
| Acurx Pharmaceuticals | $1.42 | −1.05% | $6.1M | — | — | — | — |
| Median | 22.1 | 16.0 | 2.4 | +3.0% |